Sign In
Buy CRBU
$2.00
-0.320 (-13.79%)
At Close: Jun 03, 2026
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect
10:00am, Tuesday, 18'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")
NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation
10:00am, Tuesday, 11'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company")
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates
06:16pm, Monday, 10'th Mar 2025
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.39 per share a year ago.
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:05pm, Monday, 10'th Mar 2025
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases --
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Caribou Biosciences, Inc. (NASD
Class Action Filed Against Caribou Biosciences, Inc. (CRBU) Seeking Recovery for Investors – Contact Levi & Korsinsky
06:30pm, Monday, 24'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal se
CRBU Deadline: CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit
05:05pm, Monday, 24'th Feb 2025
NEW YORK , Feb. 24, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Caribou Biosciences, Inc. (NASDAQ: CRBU) between July 14, 2023 and July
February 24, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - CRBU
04:15pm, Monday, 24'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal se
Investors can contact the law firm at no cost to learn more about recovering their losses
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal se
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Caribou Biosciences, Inc. (CRBU) Shareholders
12:07pm, Monday, 24'th Feb 2025
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securi
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal se
NEW YORK CITY, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ca
